Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. - Wikidata - awgldk - TriplyDB

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

http://www.wikidata.org/entity/Q45355102

about

Rituximab for troublesome cases of childhood nephrotic syndrome.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Rituximab in idiopathic nephrotic syndrome: does it make sense?Is rituximab effective in childhood nephrotic syndrome? Yes and no.Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome.T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.Minimal Change Disease.Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.

P2860

Q34683518-30DC7C0D-8F7F-4E22-897D-79FD4062E541 Q35040896-0CF5E7B7-4817-4B50-9FD3-E976F7E17766 Q37108328-DA72B179-44C1-4EB4-B77B-337B87EAE087 Q37261621-96731F6C-1836-420E-9F35-5A96A1CBA547 Q37375752-911AE8DE-327E-4C28-9B7D-2EA1F1B7CADE Q38118894-FDCDACD8-3E88-4EF6-97BA-968DF40B425B Q38569641-2BE5E162-9948-4406-93E6-0FA8BF796E4F Q38679589-8B4D68A4-02E3-43C4-ABFC-1D0A749AFAD8 Q38701126-CD630D40-1B9B-4512-8B85-33B75D213A4C Q38895019-7E78AC68-6585-4359-BA6F-CBBF7521286F Q39456170-D55002DF-FDEE-477B-906C-D6D7B254487A Q39573394-0D0D397A-3021-4C02-923F-74B2238790D2 Q40572300-7A2F0341-0064-40FB-AD70-39A250B7828E Q41387077-4E8278F0-E014-46FB-B9A1-5677ECB2B95A Q42083009-18188386-7DF7-4159-AE19-147866ED8A46 Q43506114-BCBD745D-2810-44AD-99E2-B41E5BDCAEFD Q52945061-2B1C8DA0-6CEA-4FF9-8B21-E7C028D8CA59 Q53838634-7AB97352-8C0B-4985-98FC-9782782A3845 Q54588259-2B8B3E0D-85E2-4F5F-AA32-0D8C5E4C841C

P2860

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

http://www.wikidata.org/entity/Q45355102

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@en

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@nl

type

label

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@en

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@nl

prefLabel

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@en

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@nl

P1433

Q45355102-31D3953B-2C12-4457-9C51-E9779E422A52

P1476

Q45355102-C425F154-198D-4D0C-8D10-D19467EB7585

P2093

Q45355102-3816E437-8720-4C4E-8E8F-9431931775D3

Q45355102-3CFC8424-7DF5-4885-BBFB-956BE02C1B3B

Q45355102-41F1D384-F636-43D5-AC46-4C2E975ADBAB

Q45355102-587CAD99-DB1D-49E2-BB0B-CE4879702848

Q45355102-643E51BA-EDA5-402F-903E-C75D974060B5

Q45355102-70B21E6E-E0F0-48E7-A2A2-C3A4E51C540C

Q45355102-7C82A0C8-FB81-4512-B956-EFC986F3F1DD

Q45355102-86794285-BFDB-47FC-979C-93B6565C5E95

Q45355102-AB151024-40C9-480B-BA6F-29FE824A57A0

Q45355102-BEE41E26-26F5-421B-947B-543EEDD75123

P2860

Q45355102-062AD318-FCAF-4DC8-859E-31C9E70F0797

Q45355102-13F0B8B2-4D27-4015-8BF2-875254B5C852

Q45355102-2253D8BE-4B76-4DC5-92F8-FE03B9FA45B2

Q45355102-2BB1FF69-3A15-40B9-8959-191573FA2E59

Q45355102-3C8ED685-14D1-4E87-874C-E06761222E3A

Q45355102-4D090042-068C-4B7A-B46C-0E6905EF9F69

Q45355102-9F373E4E-01E2-487F-BECC-8BA2C699B5AF

Q45355102-B49815E4-FE7D-4118-83F9-6C80152A8D7D

Q45355102-B5F87A73-AF99-4643-8863-3B552D5ED6B8

Q45355102-B674111E-0C40-48E0-95F7-A2DE2C87A6D1

P2888

Q45355102-A05301DD-D2C4-49F3-A772-674C9C43F66E

P304

Q45355102-E1F6219A-0A27-406D-A1C4-D1BAB1B3F8C4

P31

Q45355102-AE874B63-A42D-4DD5-8918-8E9E9E7AF72F

P356

Q45355102-CAC7A3E5-6B86-42CA-A3B6-27AA0A387175

P433

Q45355102-F0098729-129A-4B0A-BABF-D49802506703

P478

Q45355102-5ABC869B-B5CC-4F2E-8D64-4CA17479C49D

P50

Q45355102-5BC5C80A-191D-4085-AD21-F91A6C6D5431

P577

Q45355102-4EF2A4F4-4705-4ACE-800D-9D0CB0B04B54

P6179

Q45355102-33C792F3-70FB-4C46-9319-61DDAD120314

P698

Q45355102-BC06E788-9A65-4CDC-BE55-C451632CD930

P356

S00467-012-2406-3

P1433

Pediatric Nephrology

P1476

Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

@en

P2093

Arnaud Garnier

http://www.w3.org/2001/XMLSchema#string

Aurélia Bertholet-Thomas

http://www.w3.org/2001/XMLSchema#string

Brigitte Llanas

http://www.w3.org/2001/XMLSchema#string

Christine Pietrement

http://www.w3.org/2001/XMLSchema#string

Flavio Bandin

http://www.w3.org/2001/XMLSchema#string

Karine Brochard

http://www.w3.org/2001/XMLSchema#string

Lydia Ichay

http://www.w3.org/2001/XMLSchema#string

Mathilde Cailliez

http://www.w3.org/2001/XMLSchema#string

Olivier Dunand

http://www.w3.org/2001/XMLSchema#string

Stéphane Decramer

http://www.w3.org/2001/XMLSchema#string

P2860

JC virus evolution and its association with human populations

NF-kappa B p65 antagonizes IL-4 induction by c-maf in minimal change nephrotic syndrome

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract.

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development.

Evaluation and management of steroid-sensitive nephrotic syndrome.

Monoclonal antibody therapy-associated neurological disorders.

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

Rituximab for refractory focal segmental glomerulosclerosis.

P2888

s00467-012-2406-3

P304

911-918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-012-2406-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Vincent Guigonis

P577

2013-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011349484

http://www.w3.org/2001/XMLSchema#string

P698

23340857

http://www.w3.org/2001/XMLSchema#string